Evidence map›Paper›PMID 41399806›Full record

ArticleMolecular therapy. Nucleic acids2025

Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy.

Elaine Y Kang, Dongfang Wang, Damian Kaniowski, Wilson Tang, Alicia Davis, Piotr Swiderski, Marcin Kortylewski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elaine Y KangDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
Dongfang WangDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
Damian KaniowskiDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
Wilson TangDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
Alicia DavisCenter for Gene Therapy, Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, Duarte, CA 91010, USA.
Piotr SwiderskiDNA/RNA Synthesis Core Facility, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Marcin KortylewskiDepartment of Immuno-Oncology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemiaR01CA284593 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Susanta K Hui, Marcin Kortylewski · 2023 to 2026
$2.8M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA284593
6 · The paper itself

Abstract

We previously demonstrated that blocking tolerogenic signal transducer and activator of transcription 3 (STAT3) signaling in the tumor microenvironment can unleash Toll-like receptor 9 (TLR9)-mediated antitumor immunity. To enable systemic administration of minimally modified CpG-siSTAT3, we developed a panel of MC3-based lipid nanoparticle (LNP) formulations optimized for targeting immune cells and B cell lymphoma cells. The selected LNP2(CpG-siSTAT3) induced potent type I interferon (IFN) production in human peripheral blood mononuclear cells (PBMCs) and resulted in >50% STAT3 knockdown in human cancer cells at low oligonucleotide concentrations.

Indexed as

B cell lymphomacancer immunotherapyCpG oligonucleotideslipid nanoparticlesMT: Delivery StrategiessiRNASTAT3TLR9

Identifiers

PMID41399806
PMCPMC12701985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.